VIDEO: Encouraging results for triplet regimen among patients with acute myeloid leukemia

ByRichard M. Stone, MD

ByCory Perla

Fact checked byMindy Valcarcel, MS

NEW ORLEANS — In this video perspective Richard M Stone, MD, discusses data on the triplet combination regimen of azacitidine with venetoclax and magrolimab.

The results, presented by Naval Daver, MD, of he MD Anderson Cancer Center in Houston at ASH nnual eeting showed high response rates in older and high-risk patients with newly diagnosed acute myeloid leukemia.

"The response rate was high and the rate was high in those that responded; that was encouraging, Stone, professor of medicine at Harvard Medical school and director translation research adult leukemia program at Dana Farber Institute, said.

Reference:

Daver N, et al. Abstract 61. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Stone reports serving in consultancy roles for AbbVie, Astellas, Bristol Myers Squibb, BerGenBio, Boston Pharmaceuticals, Elevate Bio, Epizyme, Foghorn Therapeutics, GEMoaB, GSK, Innate, Janssen, Jazz, Kura Oncology, Novartis, OncoNova, Syndax, Syntrix and Syros.

Take Homes in Leukemia

Read more

VIDEO: Encouraging results for triplet regimen among patients with acute myeloid leukemia

Reference:

Related Content